Investigating CAPGDF15 Levels in Pregnant Women
Is the Plasma Concentration of CAPGDF15 Increased in Pregnancy? A Pilot Study
This study is testing if levels of a specific protein called CAPGDF15 change during pregnancy in healthy women compared to those who are not pregnant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 6 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | University of Copenhagen Academic / other |
| Locations | 2 sites (Copenhagen and 1 other locations) |
| Trial ID | NCT06268353 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to explore whether the plasma concentration of CAPGDF15, a small peptide associated with the hormone GDF15, increases during pregnancy. The study will involve six healthy women, three in their third trimester of pregnancy and three matched non-pregnant controls based on age and weight. Participants will undergo a single visit where a routine blood sample will be taken to measure CAPGDF15 levels. The findings may provide insights into the role of CAPGDF15 in pregnancy and its potential implications for maternal health.
Who should consider this trial
Good fit: Ideal candidates include healthy women in their third trimester of pregnancy and matched non-pregnant women who are also healthy and fit.
Not a fit: Patients with ongoing illnesses or those taking medication may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of hormonal changes during pregnancy and their implications for maternal and fetal health.
How similar studies have performed: While the specific investigation of CAPGDF15 is novel, studies on GDF15 and its implications in pregnancy have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy and fit pregnant women in the 3rd trimester. * Healthy control subjects will be matched based on age and weight and must not be taking medication. Exclusion Criteria: * Ongoing illness and/or medication intake
Where this trial is running
Copenhagen and 1 other locations
- August Krogh Building — Copenhagen, Denmark (Recruiting)
- University of Copenhagen, August Krogh Section for Molecular Physiology — Copenhagen, Østerbro, Denmark (Recruiting)
Study contacts
- Study coordinator: Erik A Richter, MD
- Email: erichter@nexs.ku.dk
- Phone: +4528751626
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.